1. Kanamori M, Takami H, Yamaguchi S, Sasayama T, Yoshimoto K, Tominaga T, Inoue A, Ikeda N, Kambe A, Kumabe T, Matsuda M, Tanaka S, Natsumeda M, Matsuda KI, Nonaka M, Jun K, Yamaoka M, Kagawa N, Shinojima N, Negoto T, Nakahara Y, Arakawa Y, Hatazaki S, Shimizu H, Yoshino A, Abe H, Akimoto J, Kawanishi Y, Suzuki T, Natsume A, Nagane M, Akiyama Y, Keino D, Fukami T, Tomita T, Kanaya K, Tokuyama T, Izumoto S, Nakada M, Kuga D, Yamamoto S, Anei R, Uzuka T, Fukai J, Kijima N, Terashima K, Ichimura K, Nishikawa R: So-called bifocal tumors" with diabetes insipidus and negative tumor markers: Are they all germinoma? Neuro Oncol. 2021, 23(2):295-303, doi: 10.1093/neuonc/noaa199."
2. Osada Y, Saito R, Shibahara I, Sasaki K, Shoji T, Kanamori M, Sonoda Y, Kumabe T, Watanabe M, Tominaga T: H3K27M and TERT promoter mutations are poor prognostic factors in surgical cases of adult thalamic high-grade glioma. Neurooncol Adv. 2021, 3(1): vdab038., doi: 10.1093/noajnl/vdab038.
3. Osada Y, Saito R, Miyata S, Shoji T, Shibahara I, Kanamori M, Sonoda Y, Kumabe T, Watanabe M, Tominaga T: Association between IDH mutational status and tumor-associated epilepsy or venous thromboembolism in patients with grade II and III astrocytoma. Brain Tumor Pathol. 2021, 38:218-227, doi: 10.1007/s10014-021-00406-1.
4. Takami H, Satomi K, Fukuoka K, Fukushima S, Matsushita Y, Yamasaki K, Nakamura T, Tanaka S, Mukasa A, Saito N, Suzuki T, Yanagisawa T, Nakamura H, Sugiyama K, Tamura K, Maehara T, Nakada M, Nonaka M, Asai A, Yokogami K, Takeshima H, Iuchi T, Kanemura Y, Kobayashi K, Nagane M, Kurozumi K, Yoshimoto K, Matsuda M, Matsumura A, Hirose Y, Tokuyama T, Kumabe T, Narita Y, Shibui S, Nakazato Y, Nishikawa R, Matsutani M, Ichimura K: Low tumor cell content predicts favorable prognosis in germinoma patients. Neurooncol Adv. 2021, 10;3(1):vdab110. doi: 10.1093/noajnl/vdab110.
5. Narita Y, Muragaki Y, Kagawa N, Asai K, Nagane M, Matsuda M, Ueki K, Kuroda J, Date I, Kobayashi H, Kumabe T, Beppu T, Kanamori M, Kasai S, Nishimura Y, Xiong H, Ocampo C, Yamada M, Mishima K: Safety and Efficacy of Depatuxizumab Mafodotin in Japanese Patients With Malignant Glioma: A Non-randomized, Phase 1/2 Trial. Cancer Sci. 2021, 112(12):5020-5033, doi: 10.1111/cas.15153.
6. Satomi K, Takami H, Fukushima S, Yamashita S, Matsushita Y, Nakazato Y, Suzuki T, Tanaka S, Mukasa A, Saito N, Kanamori M, Kumabe T, Tominaga T, Kobayashi K, Nagane M, Iuchi T, Yoshimoto K, Tamura K, Maehara T, Sakai K, Sugiyama K, Yokogami K, Takeshima H, Nonaka M, Asai A, Ushijima T, Matsutani M, Nishikawa R, Ichimura K: 12p gain is predominantly observed in non-germinomatous germ cell tumors and identifies an unfavorable subgroup of central nervous system germ cell tumors. Neuro Oncol. 2021 Oct 26:noab246. doi: 10.1093/neuonc/noab246. Online ahead of print
7. Hyakutake Y, Shibahara I, Inukai M, Koizumi H, Hide T, Morota N, Yoshida T, Sasaki J, Kumabe T: A Case of Synchronous Occurrence of Intracranial Germinoma and Systemic Sarcoidosis. NMC Case Rep J. 2021, 16;8(1):645-650, 2021, doi: 10.2176/nmccrj.cr.2021-0078.
8. 柴原一陽、隈部俊宏:脳梁進展している神経膠腫に対する摘出術.脳神経外科速報, 2021,31(4):700-709
9. Aoki K, Suzuki H, Yamamoto T, Yamamoto KN, Maeda S, Okuno Y, Ranjit M, Motomura K, Ohka F, Tanahashi K, Hirano M, Nishikawa T, Shimizu H, Kitano Y, Yamaguchi J, Yamazaki S, Nakamura H, Takahashi M, Narita Y, Nakada M, Deguchi S, Mizoguchi M, Momii Y, Muragaki Y, Abe T, Akimoto J, Wakabayashi T, Saito R, Ogawa S, Haeno H, Natsume A. Mathematical Modeling and Mutational Analysis Reveal Optimal Therapy to Prevent Malignant Transformation in Grade II IDH-Mutant Gliomas. Cancer Res. 2021, 81(18): 4861-4873. doi: 10.1158/0008-5472.CAN-21-0985.
10. Yamazaki S, Ohka F, Hirano M, Shiraki Y, Motomura K, Tanahashi K, Tsujiuchi T, Motomura A, Aoki K, Shinjo K, Murofushi Y, Kitano Y, Maeda S, Kato A, Shimizu H, Yamaguchi J, Adilijiang A, Wakabayashi T, Saito R, Enomoto A, Kondo Y, Natsume A. Newly established patient-derived organoid model of intracranial meningioma. Neuro Oncol. 2021, 23, 1936-1948. doi: 10.1093/neuonc/noab155.